DE VITA, Salvatore
 Distribuzione geografica
Continente #
NA - Nord America 32.585
AS - Asia 13.311
EU - Europa 9.120
SA - Sud America 2.701
Continente sconosciuto - Info sul continente non disponibili 947
AF - Africa 292
OC - Oceania 19
AN - Antartide 2
Totale 58.977
Nazione #
US - Stati Uniti d'America 31.890
SG - Singapore 6.209
CN - Cina 2.726
UA - Ucraina 2.503
BR - Brasile 2.139
HK - Hong Kong 1.486
DE - Germania 1.347
IT - Italia 1.310
VN - Vietnam 1.043
FI - Finlandia 804
RU - Federazione Russa 628
FR - Francia 584
SE - Svezia 524
IE - Irlanda 482
GB - Regno Unito 430
CA - Canada 384
IN - India 349
TR - Turchia 269
KR - Corea 262
BD - Bangladesh 201
AR - Argentina 186
MX - Messico 123
EC - Ecuador 110
IQ - Iraq 95
ID - Indonesia 90
JP - Giappone 83
ZA - Sudafrica 83
NL - Olanda 75
CO - Colombia 74
PL - Polonia 70
AT - Austria 68
PK - Pakistan 64
MA - Marocco 51
PH - Filippine 51
CL - Cile 47
ES - Italia 47
IR - Iran 46
VE - Venezuela 46
UZ - Uzbekistan 45
SA - Arabia Saudita 44
PY - Paraguay 40
CZ - Repubblica Ceca 36
BE - Belgio 34
EG - Egitto 33
JM - Giamaica 31
CR - Costa Rica 28
EU - Europa 27
MY - Malesia 25
UY - Uruguay 24
LT - Lituania 23
TG - Togo 22
IL - Israele 21
TT - Trinidad e Tobago 21
PE - Perù 20
TN - Tunisia 20
AE - Emirati Arabi Uniti 19
NP - Nepal 19
PT - Portogallo 18
AZ - Azerbaigian 16
CH - Svizzera 16
DO - Repubblica Dominicana 16
KE - Kenya 16
GR - Grecia 15
GT - Guatemala 15
HN - Honduras 15
JO - Giordania 15
KZ - Kazakistan 15
BO - Bolivia 14
LB - Libano 14
NI - Nicaragua 14
AL - Albania 13
AU - Australia 13
DZ - Algeria 13
EE - Estonia 12
RO - Romania 12
OM - Oman 11
PS - Palestinian Territory 11
TH - Thailandia 11
DK - Danimarca 10
ET - Etiopia 10
TW - Taiwan 10
HR - Croazia 9
KG - Kirghizistan 9
PA - Panama 9
LK - Sri Lanka 8
NO - Norvegia 8
SV - El Salvador 8
BB - Barbados 7
AM - Armenia 6
CW - ???statistics.table.value.countryCode.CW??? 6
GP - Guadalupe 6
HU - Ungheria 6
KW - Kuwait 6
NG - Nigeria 6
RS - Serbia 6
SN - Senegal 6
SY - Repubblica araba siriana 6
BG - Bulgaria 5
LV - Lettonia 5
NZ - Nuova Zelanda 5
Totale 57.963
Città #
Woodbridge 3.782
Ann Arbor 2.593
Singapore 2.512
Ashburn 2.413
Fairfield 2.015
Houston 2.004
Jacksonville 1.771
San Jose 1.569
Chandler 1.523
Hong Kong 1.459
Beijing 1.310
Wilmington 1.006
Dearborn 968
Council Bluffs 935
Seattle 721
Boardman 663
Cambridge 616
Dublin 474
Princeton 468
Lauterbourg 466
Los Angeles 400
Ho Chi Minh City 348
Udine 305
Hefei 254
São Paulo 241
Seoul 239
Buffalo 237
Dallas 235
Helsinki 227
Santa Clara 219
Hanoi 213
Munich 199
San Diego 197
Izmir 192
New York 180
The Dalles 157
Redondo Beach 136
Ottawa 132
Des Moines 106
Ogden 104
Norwalk 92
Phoenix 89
Toronto 83
Dong Ket 78
Mumbai 75
Milan 74
Orem 74
Nuremberg 66
Chicago 65
Rome 63
Brooklyn 60
Frankfurt am Main 60
Nanjing 60
Montreal 58
Tokyo 58
Trieste 58
London 56
Belo Horizonte 55
Rio de Janeiro 55
Redmond 54
Atlanta 52
Guangzhou 50
Warsaw 46
Denver 44
Johannesburg 44
North Bergen 43
San Mateo 43
Kunming 42
Falls Church 41
Guayaquil 39
San Francisco 39
Tashkent 39
Haiphong 38
Mexico City 38
Quito 38
Chennai 37
Shanghai 37
Baghdad 36
Brasília 36
Da Nang 36
Amsterdam 34
Salvador 34
Stockholm 33
Washington 33
Naples 32
Boston 30
Curitiba 30
Turku 30
Augusta 29
Brussels 29
Pittsburgh 29
Vienna 29
Manchester 28
Philadelphia 27
Bar Harbor 26
Brno 26
Campinas 26
Düsseldorf 26
Hải Dương 26
Lahore 26
Totale 36.323
Nome #
Gastric B-cell clonal expansion and Helicobacter pylori infection in patients with autoimmune diseases and with dyspepsia. A follow-up study. 328
Factors and comorbidities associated with first neuropsychiatric event in systemic lupus erythematosus: does a risk profile exist? A large multicentre retrospective cross-sectional study on 959 Italian patients 307
Efficacy and safety of belimumab in primary Sjogren's syndrome: results of the BELISS open-label phase II study. 211
Differentiation between early rheumatoid and early psoriatic arthritis by the ultrasonographic study of the synovio-entheseal complex of the small joints of the hands 208
B-cell clonal expansion in gastric biopsies of patients with dyspepsia and autoimmune diseases: effect of H. Pylori eradication. 207
EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjogren's syndrome. 206
Knuckle pads mimic early psoriatic arthritis 202
Absence of human parvovirus B19 DNA in myoepithelial sialadenitis of primary Sjögren's syndrome. 201
A randomized controlled trial of rituximab for treatment of severe cryoglobulinemic vasculitis. 198
A snapshot on the on-label and off-label use of the interleukin-1 inhibitors in Italy among rheumatologists and pediatric rheumatologists: A nationwide multi-center retrospective observational study 198
Development of the ClinESSDAI: A clinical score without biological domain. A tool for biological studies 196
Validation of the classification criteria for cryoglobulinaemic vasculitis. 195
Gitelman syndrome disclosed by calcium pyrophosphate deposition disease: Early diagnosis by ultrasonographic study 194
Biomarkers of lymphoma in Sjögren's syndrome and evaluation of the lymphoma risk in prelymphomatous conditions: results of a multicenter study. 193
Terapia dell'artrite reumatoide con immunoglobuline per via endovenosa ad alte dosi: esperienza clinica e revisione della letteratura 192
Acetaminophen-induced liver injury in a woman with febrile flare of systemic lupus erythematosus 192
A randomized, controlled, multicenter phase iii study of the efficacy and safety of rituximab (rtx) monotherapy versus the best available treatment (bat) in patients with mixed cryoglobulinemia syndrome (MC) Ann Rheum Dis 2010;69(Suppl3):93 191
AB0695 Anti-prothrombin/phosphatidyl-serine complex autoantibodies in antiphospholipid syndrome: Preliminary data using a new ELISA method 190
2016 American College of Rheumatology/European League Against Rheumatism Classification Criteria for Primary Sjögren's Syndrome: A Consensus and Data-Driven Methodology Involving Three International Patient Cohorts 186
B-cell clonality and infection with Helicobacter pylori: implications for development of gastric lymphoma 184
Pachydermodactyly: The role of ultrasonography and dermoscopy for diagnosis 184
Atypical lymphoproliferation progressing into B-cell lymphoma in rheumatoid arthritis treated with different biological agents: clinical course and molecular characterization. 184
Efficacy and safety of rituximab in type II mixed cryoglobulinemia. 183
The CC homozygosis of the -174G>C IL-6 polymorphism predicts a lower efficacy of rituximab therapy in rheumatoid arthritis 183
Pregnancy and foetal outcomes following anti-tumor necrosis factor alpha therapy: A prospective multicentre study 183
EULAR Sjogren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren's syndrome. 183
Characterization of prelymphomatous stages of B cell lymphoproliferation in Sjogren's syndrome 180
Medical data quality assessment: On the development of an automated framework for medical data curation 180
Efficacy and safety of rituximab in type II mixed cryoglobulinemia 179
Retreatment regimen of rituximab monotherapy given at the relapse of severe HCV-related cryoglobulinemic vasculitis: Long-term follow up data of a randomized controlled multicentre study 178
B cell clonality in gastric lymphoid tissues of patients with Sjogren's syndrome 177
HCV-related liver and lymphoproliferative diseases: Association with polymorphisms of IL28B and TLR2 176
Recommendations for the management of mixed cryoglobulinemia syndrome in hepatitis C virus-infected patients 175
SALIVARY GLAND ECHOGRAPHY IN PRIMARY AND SECONDARY SJOGREN'S SYNDROME 174
A B-cell activating factor receptor (BAFF-R) His159Tyr mutation in Sjögren's Syndrome related lymphoproliferation 174
Efficacy of intravenous cyclosporine in a case of cytophagic histiocytic panniculitis complicated by haemophagocytic syndrome after visceral leishmania infection 174
B-cell lymphomas associated with HCV infection 173
B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia. 172
Optimizing the dose of mycophenolate mofetil for the maintenance treatment of lupus nephritis by therapeutic drug monitoring. 172
Prevalence of mixed cryoglobulinaemia syndrome and circulating cryoglobulins in a population-based survey: the Origgio study. 169
Retinoids irreversibly inhibit in vitro growth of Epstein-Barr virus-immortalized B lymphocytes. 169
Hepatitis C virus, non-Hodgkin's lymphomas and hepatocellular carcinoma 169
Use of teriparatide in osteoporosis due to active rheumatic diseases 169
BLyS upregulation in Sjogren's syndrome associated with lymphoproliferative disorders, higher ESSDAI score and B-cell clonal expansion in the salivary glands 169
Treatment with belimumab restores B cell subsets and their expression of B cell activating factor receptor in patients with primary Sjogren's syndrome 169
Emerging drugs for primary Sjögren’s syndrome 168
Clinical and biological differences between cryoglobulinaemic and hypergammaglobulinaemic purpura in primary Sjögren's syndrome: results of a large multicentre study. 167
Cryoglobulinaemia related to Sjogren's syndrome or HCV infection: differences based on the pattern of bone marrow involvement, lymphoma evolution and laboratory tests after parotidectomy. 166
Misoprostol-induced urinary incontinence 166
Plasmocitoma micromolecolare osteosclerotico 165
BLyS and April serum levels in patients with autoimmune thyroid diseases. 165
Introducing treat-to-target strategies of autoimmune extrahepatic manifestations of chronic hepatitis C virus infection 165
Safety and Efficacy of Ianalumab in Patients With Sjögren's Disease: 52-Week Results From a Randomized, Placebo-Controlled, Phase 2b Dose-Ranging Study 162
Rituximab for the treatment of type II mixed cryoglobulinemia. 162
A randomized, controlled, multicenter phase III study of the efficacy and safety of rituximab (rtx) monotherapy versus the best available treatment (bat) in patients with mixed cryoglobulinemia syndrome (MC) 162
Role e of oral cyclophosphamide in the treatment of giant cell arteritis 160
Strontium ranelate and femural fracture healing during rheumatoid arthritis and osteoporosis 160
Retrospective analysis of the usefulness of a protocol with high-dose methotrexate in polymyalgia rheumatica: Results of a single-center cohort of 100 patients 160
Profiling COVID-19 pneumonia progressing into the cytokine storm syndrome: Results from a single Italian Centre study on tocilizumab versus standard of care 160
Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. 159
Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis 159
Dermoscopy of nail fold and elbow in the differential diagnosis of early psoriatic arthritis sine psoriasis and early rheumatoid arthritis 159
Patient-reported impact of spondyloarthritis on work disability and working life: The ATLANTIS survey 159
Cost-effectiveness analysis of two Rituximab retreatment regimens for longstanding rheumatoid arthritis. 159
Ciclosporina e tacrolimus nella miosite da corpi inclusi: efficacia clinica, sicurezza e risparmio nell'uso dei corticosteroidi 158
Combination therapy with cyclosporin-A plus methotrexate in adult Still’s disease: efficacy and safety. . 157
Low frequency of bcl-2 rearrangement in HCV-associated non-Hodgkin's lymphoma tissue 157
B-lymphocyte stimulator and a proliferation-inducing ligand serum levels in IgA-deficient patients with and without celiac disease 157
Treatment of rheumatoid arthritis with rituximab: an update and possible indications. 157
The 158VV Fcgamma receptor 3A genotype is associated with response to rituximab in rheumatoid arthritis: results of an Italian multicentre study. 157
Validation of EULAR primary Sjogren's syndrome disease activity (ESSDAI) and patient indexes (ESSPRI). 156
Therapeutic options after treatment failure in rheumatoid arthritis or spondyloarthritides. 156
Efficacy of selective B cell Blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells 156
Detection of DNA of Chlamydophila psittaci in subjects with psoriasis: a casual or a causal link? 156
Clinical differences between ANA/anti-ENA positive or negative primary Sjögren's syndrome 155
B-cell compartment as the selective target for the treatment of immune thrombocytopenias 155
B-cell clonality in gastric mucosa of patients with Sjögren's syndrome and connective tissue diseases: relationship with Helicobacter pylori, EBV and human herpesvirus-6 (HHV-6) infections. 155
Activation-induced cytidine deaminase expression in follicular dendritic cell networks and interfollicular large B cells supports functionality of ectopic lymphoid neogenesis in autoimmune sialoadenitis and MALT lymphoma in Sjögren's syndrome 155
Anti-SSA/SSB-negative Sjögren's syndrome shows a lower prevalence of lymphoproliferative manifestations, and a lower risk of lymphoma evolution 155
Dermoscopy in the differential diagnosis between malar rash of systemic lupus erythematosus and erythematotelangiectatic rosacea: an observational study 155
Accurate detection of changes in disease activity in primary Sjögren's syndrome by the European League Against Rheumatism Sjögren's Syndrome Disease Activity Index. 154
The Detection of Anti-adalimumab Antibodies in a Series of Inflammatory Polyarthritis: three ELISA Methods Compared 154
Subtypes of Epstein-Barr virus in HIV-1-associated and HIV-1-unrelated Hodgkin's disease cases. 154
Mycophenolic Acid AUC estimation in patients with lupus nephritis using an algorithm validated in an heart transplanted population 153
A TGF-β associated genetic score to define prognosis and platinum sensitivity in advanced epithelial ovarian cancer 153
Cryoglobulinemic vasculitis in primary Sjögren's Syndrome: Clinical presentation, association with lymphoma and comparison with Hepatitis C-related disease 153
L. Quartuccio, M. Fabris, M. Maset, E. Pontarini, A. Zabotti, S. De Vita Bone marrow b-cell expansion in mixed cryoglobulinemia: association with nephritis and response to rituximab 152
Infection of neoplastic B cells by HCV in low-grade non-Hodgkin’s lymphomas associated with type II mixed cryoglobulinemia. 152
Combinad therapy with cyclobenzaprina and ipuprofen in primary fibromialgia sindrome 152
Treatment of giant cell arteritis with cyclophosphamide pulses 151
BLyS Role in the Diagnosis and Prognosis of Neuroendocrine Tumors: Preliminary Results. 151
HCV-unrelated cryoglobulinaemic vasculitis: the results of a prospective observational study by the Italian Group for the Study of Cryoglobulinaemias (GISC) 151
B-cell lymphomagenesis and human autoimmune models. 150
Multifocal ischemic necrosis of bone in scleroderma. 150
B cell driving cytokines in eraly rheumatoid arthritis. Assessment of possibile clonal expansions during treatment with cyclosporin A. Arthritis and Rheumatism 1996; 39 (Suppl.): S26. 149
Frequent detection of human herpesvirus 6 DNA in HIV-associated lymphadenopathy. 149
General and specific factors associated with severity of cognitive impairment in systemic lupus erythematosus 149
Rituximab monotherapy, rather than rituximab plus antiviral drugs, for initial treatment of severe hepatitis C virus-associated mixed cryoglobulinemia syndrome: comment on the article by Terrier et al 149
A retrospective, multicenter study evaluating the prognostic value of minor salivary gland histology in a large cohort of patients with primary Sjögren's syndrome. 148
Genetic insights into the disease mechanisms of type II mixed cryoglobulinemia induced by hepatitis C virus 148
Totale 17.179
Categoria #
all - tutte 226.258
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 226.258


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20222.869 0 0 0 380 108 105 156 232 48 532 673 635
2022/20233.839 515 167 69 427 393 1.043 33 287 574 56 114 161
2023/20241.238 179 120 47 26 223 190 51 93 168 67 24 50
2024/20258.740 202 606 300 238 391 413 451 581 931 765 1.402 2.460
2025/202614.716 1.100 1.468 1.293 1.524 2.183 1.273 1.653 553 1.023 1.256 890 500
2026/20274.554 452 1.021 1.450 1.631 0 0 0 0 0 0 0 0
Totale 58.977